{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T15:45:04Z","timestamp":1782920704439,"version":"3.54.5"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1038\/s41375-026-02997-0","type":"journal-article","created":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T05:51:06Z","timestamp":1780465866000},"page":"1542-1546","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Inotuzumab ozogamicin in individuals with Down syndrome and acute lymphoblastic leukemia"],"prefix":"10.1038","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8099-9501","authenticated-orcid":false,"given":"Amanda M.","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Aftandilian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colleen","family":"Annesley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Colace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly E.","family":"Faulk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua W.","family":"Goldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2482-5608","authenticated-orcid":false,"given":"Erin","family":"Guest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ammar","family":"Hayani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4465-6119","authenticated-orcid":false,"given":"Elias","family":"Jabbour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjali","family":"Khanna-Farber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wade","family":"Kyono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kasey","family":"Leger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Maloney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2297-9670","authenticated-orcid":false,"given":"David","family":"McCall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holly L.","family":"Pacenta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Troy C.","family":"Quigg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy D.","family":"Rubinstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Schafer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8025-6767","authenticated-orcid":false,"given":"Susan R.","family":"Rheingold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7559-7927","authenticated-orcid":false,"given":"Deepa","family":"Bhojwani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maureen M.","family":"O\u2019Brien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4081-8195","authenticated-orcid":false,"given":"Karen R.","family":"Rabin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,3]]},"reference":[{"key":"2997_CR1","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1200\/JCO.23.00389","volume":"42","author":"KR Rabin","year":"2024","unstructured":"Rabin KR, Devidas M, Chen Z, Ji L, Kairalla J, Hitzler JK, et al. Outcomes in children, adolescents, and young adults with Down syndrome and ALL: a report from the Children\u2019s Oncology Group. J Clin Oncol. 2024;42:218\u201327.","journal-title":"J Clin Oncol"},{"key":"2997_CR2","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1182\/blood-2013-06-509463","volume":"123","author":"TD Buitenkamp","year":"2014","unstructured":"Buitenkamp TD, Izraeli S, Zimmermann M, Forestier E, Heerema NA, van den Heuvel-Eibrink MM, et al. Acute lymphoblastic leukemia in children with Down syndrome: a retrospective analysis from the Ponte di Legno study group. Blood. 2014;123:70\u20137.","journal-title":"Blood"},{"key":"2997_CR3","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1002\/pbc.24918","volume":"61","author":"JK Hitzler","year":"2014","unstructured":"Hitzler JK, He W, Doyle J, Cairo M, Camitta BM, Chan KW, et al. Outcome of transplantation for acute lymphoblastic leukemia in children with Down syndrome. Pediatr Blood Cancer. 2014;61:1126\u20138.","journal-title":"Pediatr Blood Cancer"},{"key":"2997_CR4","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1002\/cncr.32116","volume":"125","author":"HM Kantarjian","year":"2019","unstructured":"Kantarjian HM, DeAngelo DJ, Stelljes M, Liedtke M, Stock W, Gokbuget N, et al. Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study. Cancer. 2019;125:2474\u201387.","journal-title":"Cancer"},{"key":"2997_CR5","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1200\/JCO.21.01693","volume":"40","author":"MM O\u2019Brien","year":"2022","unstructured":"O\u2019Brien MM, Ji L, Shah NN, Rheingold SR, Bhojwani D, Yuan CM, et al. Phase II trial of inotuzumab ozogamicin in children and adolescents with relapsed or refractory B-cell acute lymphoblastic leukemia: Children\u2019s Oncology Group Protocol AALL1621. J Clin Oncol. 2022;40:956\u201367.","journal-title":"J Clin Oncol"},{"key":"2997_CR6","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1038\/s41375-022-01576-3","volume":"36","author":"E Pennesi","year":"2022","unstructured":"Pennesi E, Michels N, Brivio E, van der Velden VHJ, Jiang Y, Thano A, et al. Inotuzumab ozogamicin as single agent in pediatric patients with relapsed and refractory acute lymphoblastic leukemia: results from a phase II trial. Leukemia. 2022;36:1516\u201324.","journal-title":"Leukemia"},{"key":"2997_CR7","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1038\/s41375-018-0265-z","volume":"33","author":"D Bhojwani","year":"2019","unstructured":"Bhojwani D, Sposto R, Shah NN, Rodriguez V, Yuan C, Stetler-Stevenson M, et al. Inotuzumab ozogamicin in pediatric patients with relapsed\/refractory acute lymphoblastic leukemia. Leukemia. 2019;33:884\u201392.","journal-title":"Leukemia"},{"key":"2997_CR8","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1007\/s12185-024-03890-1","volume":"121","author":"A Kohso","year":"2025","unstructured":"Kohso A, Toyoda H, Hanaki R, Niwa K, Okumura Y, Morimoto M, et al. Inotuzumab ozogamicin for relapse prevention in a boy with Down syndrome and relapsed acute lymphoblastic leukemia. Int J Hematol. 2025;121:276\u201380.","journal-title":"Int J Hematol"},{"key":"2997_CR9","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.27562","volume":"66","author":"L Murillo","year":"2019","unstructured":"Murillo L, Dapena JL, Velasco P, de Heredia CD. Use of inotuzumab-ozogamicin in a child with Down syndrome and refractory B-cell precursor acute lymphoblastic leukemia. Pediatr Blood Cancer. 2019;66:e27562.","journal-title":"Pediatr Blood Cancer"},{"key":"2997_CR10","doi-asserted-by":"publisher","first-page":"e168","DOI":"10.1016\/j.clml.2023.12.016","volume":"24","author":"NJ Short","year":"2024","unstructured":"Short NJ, Jabbour E, Jamison T, Paul S, Cuglievan B, McCall D, et al. Dose-dense mini-hyper-CVD, inotuzumab ozogamicin and blinatumomab achieves rapid MRD-negativity in Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia. Clin Lymphoma Myeloma Leuk. 2024;24:e168\u2013e73.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2997_CR11","doi-asserted-by":"publisher","first-page":"3526","DOI":"10.1200\/JCO-25-00307","volume":"43","author":"MJ Wieduwilt","year":"2025","unstructured":"Wieduwilt MJ, Yin J, Kour O, Teske R, Stock W, Escherich C, et al. Inotuzumab ozogamicin then blinatumomab for older adults with newly diagnosed B-cell all: alliance study A041703 cohort 1 results. J Clin Oncol. 2025;43:3526\u201335.","journal-title":"J Clin Oncol"},{"key":"2997_CR12","doi-asserted-by":"publisher","first-page":"e433","DOI":"10.1016\/S2352-3026(23)00073-X","volume":"10","author":"E Jabbour","year":"2023","unstructured":"Jabbour E, Short NJ, Senapati J, Jain N, Huang X, Daver N, et al. Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trial. Lancet Haematol. 2023;10:e433\u2013e44.","journal-title":"Lancet Haematol"},{"key":"2997_CR13","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1002\/ajh.27576","volume":"100","author":"H Kantarjian","year":"2025","unstructured":"Kantarjian H, Short NJ, Jain N, Haddad FG, Kadia T, Yilmaz M, et al. Hyper-CVAD and sequential blinatumomab without and with inotuzumab in young adults with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia. Am J Hematol. 2025;100:402\u20137.","journal-title":"Am J Hematol"},{"key":"2997_CR14","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.31634","volume":"72","author":"AC Holland","year":"2025","unstructured":"Holland AC, Smith J, Wang L, Muller B, Inaba H. Reduced-intensity chemotherapy with immunotherapy for children with down syndrome and B-cell acute lymphoblastic leukemia. Pediatr Blood Cancer. 2025;72:e31634.","journal-title":"Pediatr Blood Cancer"},{"key":"2997_CR15","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1182\/blood-2024-194244","volume":"144","author":"DJ DeAngelo","year":"2024","unstructured":"DeAngelo DJ, Chen Y, Cassaday RD, Hibma J, Yang DZ, Garrett M, et al. Dose optimization of inotuzumab ozogamicin in adult patients with relapsed\/refractory acute lymphoblastic leukemia. Blood. 2024;144:732.","journal-title":"Blood"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-02997-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-02997-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-02997-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T14:53:55Z","timestamp":1782917635000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-02997-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,3]]},"references-count":15,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["2997"],"URL":"https:\/\/doi.org\/10.1038\/s41375-026-02997-0","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,3]]},"assertion":[{"value":"31 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"EG \u2013 Amgen (employment, stock); KL \u2013 Jazz Pharmaceuticals (consultant), Servier (consultant); DM \u2013 Abbvie (research funding), Crossbow Therapeutics (research funding), Kura Oncology (research funding), Gateway for Cancer Research (research funding), MD Education (travel accommodations and speaker honorarium), Servier (research funding); TCQ \u2013 Jazz Pharmaceuticals (speaker\u2019s bureau); SRR \u2013 Pfizer (consultant), AbbVie (consultant); DB \u2013 Wugen (research funding); MMO\u2019B \u2013 Pfizer (research funding and consultant). The remaining authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}